Anil Chagarlamudi, MD
Interventional Cardiology · Houma, LANPI 1952308959
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Venclose Inc. at 37.7% of the total.
Across 234 payments — averaging $114.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Venclose Inc.$10K
- Angiodynamics, Inc.$7K
- Penumbra, Inc.$4K
- Abiomed$1K
- Boehringer Ingelheim$656
- Philips North America LLC$646
- plus $4K from 28 others
What the payments were for
- Consulting fees$4,00015%
- Speaking & faculty fees$6,00022%
- Travel & lodging$5,02619%
- Food & beverage$10,22038%
- Other$1,6006%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Venclose Inc. | 5 | $10,121 |
| Angiodynamics, Inc. | 35 | $6,744 |
| Penumbra, Inc. | 16 | $3,931 |
| Abiomed | 34 | $1,024 |
| Boehringer Ingelheim | 11 | $656 |
| Philips North America LLC | 12 | $646 |
| Medtronic(2 entities) | 30 | $560 |
| Boston Scientific | 13 | $515 |
| Novo Nordisk | 5 | $284 |
| Shockwave Medical, Inc | 2 | $261 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $237 |
| Abbott | 4 | $229 |
| Amgen | 8 | $223 |
| Cardiac Dimensions, Inc. | 1 | $179 |
| Novartis | 8 | $145 |
| AstraZeneca | 4 | $143 |
| Bayer | 1 | $122 |
| Cordis US CORP. | 2 | $115 |
| GE HealthCare | 2 | $97 |
| Johnson & Johnson | 6 | $89 |
| Merck | 5 | $86 |
| Cardiva Medical, Inc. | 3 | $84 |
| Silk Road Medical, Inc. | 1 | $60 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Terumo Medical Corporation | 2 | $40 |
| Inari Medical, Inc. | 2 | $37 |
| Contego Medical, Inc | 1 | $24 |
| Asahi Intecc USA, Inc. | 1 | $23 |
| Endologix LLC | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Stryker | 1 | $20 |
| Biocompatibles, Inc. | 1 | $19 |
| Pfizer | 1 | $17 |
| Veryan Medical Incorporated | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Venclose$6,000
- Indigo System$1,935
- AngioVac$1,781
- AlphaVac$1,766
- RUBY Coil$1,706
- VenaCure 1470 Pro$1,600
- Auryon Laser System 100-120 Vac$387
- JARDIANCE$370
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$261
- Impella$253
- (6391) Nexcimer$239
- Ozempic$237
- COREVALVE EVOLUT R$162
- Labosys$129
- CARDIOMEMS$123
- Kerendia$122
- Repatha$105
How this compares
$26,846 in reported general payments places this provider in the 75th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 53 | $35,936 |
| EntrestoSacubitril/Valsartan | 13 | $11,871 |
| BrilintaTicagrelor | 17 | $8,291 |
| JardianceEmpagliflozin | 13 | $7,801 |
| Prasugrel Hcl | 15 | $567 |
| Metoprolol Succinate | 67 | $514 |
| ClopidogrelClopidogrel Bisulfate | 64 | $398 |
| Rosuvastatin Calcium | 26 | $231 |
| Atorvastatin Calcium | 24 | $125 |
| Nifedipine ErNifedipine | 12 | $125 |
| Amiodarone Hcl | 29 | $105 |
| Metoprolol Tartrate | 20 | $98 |
| Valsartan | 11 | $79 |
| Pantoprazole Sodium | 13 | $75 |
| Lisinopril | 25 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $35,93653 claims |
| NovartisEntresto | $145 | $11,87113 claims |
| AstraZenecaBrilinta | $143 | $8,29117 claims |
| Boehringer IngelheimJardiance | $656 | $7,80113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Houma
- Craig WalkerHouma$5M
- Pradeep NairHouma$212K
- Richard AbbenHouma$101K
- Matthew FinnHouma$69K
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
- Rajan PatelNew Orleans$517K
- Agostino IngraldiLafayette$315K
- Steven BaileyShreveport$305K
- James JenkinsNew Orleans$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.